시장보고서
상품코드
1274820

세계의 미세잔존질환(MRD) 검사 시장 : 검사 유형, 기술, 용도, 최종사용자, 지역별 - 시장 규모, 점유율, 동향 분석, 기회, 예측(2019-2029년)

Minimal Residual Disease Testing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Test Type ; By Technology ; By Application ; By End Use ; By Region

발행일: | 리서치사: Blueweave Consulting & Research Private Limited | 페이지 정보: 영문 400 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 미세잔존질환(MRD) 검사 시장 규모는 2022년 15억 4,000만 달러에서 예측 기간 중 14.6%의 CAGR로 추이하며, 2029년에는 39억 6,000만 달러 규모로 성장할 것으로 예측됩니다.

세계의 미세잔존질환(MRD) 검사 시장은 정밀의료 어프로치의 높은 채택률, 암의 조기진단·발견에 대한 동향의 증가, 세계에서 암 유병률의 증가에 의해 정확하고 신뢰성 높은 진단 검사에 대한 수요가 급증하고 있는 것으로 인해 호황을 보이고 있습니다.

세계의 미세잔존질환(MRD) 검사 시장을 조사했으며, 시장 개요, 시장 성장에 대한 각종 영향요인 분석, 기술 동향, 법규제 환경, 시장 규모의 추이·예측, 각종 구분·지역/주요 국가별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 조사 프레임워크

제2장 주요 요약

제3장 세계의 미세잔존질환(MRD) 검사 시장에 관한 인사이트

  • 산업의 밸류체인 분석
  • DROC 분석
    • 촉진요인
    • 억제요인
    • 기회
    • 과제
  • 기술의 진보/최근 개발
  • 규제 프레임워크
  • Porter's Five Forces 분석

제4장 세계의 미세잔존질환(MRD) 검사 시장 : 개요

  • 시장 규모·예측
  • 시장 점유율·예측
  • 검사 유형별
    • DNA 기반 검사
    • RNA 기반 검사
    • 면역학적 검사
    • 기타
  • 기술별
    • NGS·PCR
    • 유세포분석
    • 형광 In-Situ 하이브리다이제이션
    • 기타
  • 용도별
    • 혈액 악성 종양
    • 고형 종양
    • 기타
  • 최종사용자별
    • 병원
    • 전문 클리닉
    • 진단 랩
    • 연구·학술기관
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카

제5장 북미의 미세잔존질환(MRD) 검사 시장

  • 시장 규모·예측
  • 시장 점유율·예측
    • 검사 유형별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별

제6장 유럽의 미세잔존질환(MRD) 검사 시장

  • 시장 규모·예측
  • 시장 점유율·예측
    • 검사 유형별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별

제7장 아시아태평양의 미세잔존질환(MRD) 검사 시장

  • 시장 규모·예측
  • 시장 점유율·예측
    • 검사 유형별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별

제8장 라틴아메리카의 미세잔존질환(MRD) 검사 시장

  • 시장 규모·예측
  • 시장 점유율·예측
    • 검사 유형별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별

제9장 중동 및 아프리카의 미세잔존질환(MRD) 검사 시장

  • 시장 규모·예측
  • 시장 점유율·예측
    • 검사 유형별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별

제10장 경쟁 구도

  • 주요 기업·제품 리스트
  • 시장 점유율 분석
  • 경쟁 벤치마킹 : 경영 파라미터별
  • 주요 전략적 개발(M&A·제휴 등)

제11장 세계의 미세잔존질환(MRD) 검사 시장에 대한 COVID-19의 영향

제12장 기업 개요(기업 개요·재무 매트릭스·경쟁 구도·주요 인재·주요 경쟁 상대·연락처·전략적 전망·SWOT 분석)

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies
  • ARUP Laboratories
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Janssen Diagnostics LLC
  • Luminex Corporation
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • QIAGEN N.V.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
  • 기타 주요 기업

제13장 주요 전략적 제안

제14장 조사 방법

KSA 23.05.25

Global Minimal Residual Disease Testing Market Size More Than Doubles to Reach USD 4 Billion by 2029.

Global minimal residual disease testing market is flourishing because of high adoption of precision medicine approaches, growing trend towards early cancer diagnosis and detection, and increasing prevalence of cancer worldwide, leading to surging demand for accurate and reliable diagnostic tests.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global minimal residual disease testing market size at USD 1.54 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global minimal residual disease testing market size to grow at a significant CAGR of 14.6% reaching a value of USD 3.96 billion by 2029. Major growth drivers for global minimal residual disease testing market include growing cancer patient population, awareness among consumers of the importance of therapy, as well as increased investments in research, and high disposable income in developing nations. A primary growth driver of the market growth is the escalating prevalence of cancer. According to the World Health Organization, cancer is currently the second most common cause of death worldwide. In 2020, there were 19.3 million reported cases of cancer and 9.96 million deaths related to the disease. The International Agency for Research on Cancer predicts that the number of cancer cases will rise to 21.9 million by 2025 and 24.6 million by 2030. As a result, governments are expected to establish new cancer screening programs to address this surge in cases. Also, the market is expected to experience growth due to increased investments in MRD (minimal residual disease) testing programs. MRD diagnostic and monitoring research is expanding, which is creating demand for these services. However, limited availability of skilled healthcare professionals to perform and interpret MRD tests and concerns over the accuracy and reliability of MRD tests are anticipated to restrain the overall market growth.

Global Minimal Residual Disease Testing Market - Overview:

Global minimal residual disease (MRD) testing market refers to the market for diagnostic tests used to detect the presence of cancer cells in patients who have undergone treatment. MRD testing is a highly sensitive and specific technique that is capable of detecting small amounts of cancer cells that may remain in a patient's body after treatment. The MRD testing market includes products and services such as assays, flow cytometers, and other testing equipment, as well as related services like sample preparation and analysis. The market caters to healthcare providers, research organizations, and pharmaceutical companies who use MRD testing for disease monitoring, treatment selection, and clinical trial endpoints.

Impact of COVID-19 on Global Minimal Residual Disease Testing Market

COVID-19 had a detrimental impact on the global minimal residual disease (MRD) testing market. With the focus on the virus and the strain on healthcare systems, the demand for MRD testing was affected. The restrictions imposed due to the pandemic, such as social distancing and lockdown measures, have also resulted in delays or cancellations of elective procedures, including MRD testing. Also, the disruption in the supply chain and manufacturing processes has led to a shortage of necessary components and instruments required for testing. The uncertain economic conditions and reduced funding for research and development may further impede the growth of the MRD testing market in the near future.

Global Minimal Residual Disease Testing Market - By Test Type

Based on test type, the global minimal residual disease testing market is divided into DNA-Based Test, RNA-Based Test, and Immunological Test segments. The DNA-based tests segment held the highest share of the MRD testing market due to their high sensitivity and specificity in detecting cancer cells. However, the RNA-based tests segment is expected to grow at the highest CAGR during the forecast period due to advancements in technologies like next-generation sequencing (NGS) and digital PCR.

Competitive Landscape:

Major players operating in the global minimal residual disease testing market include: Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, ARUP Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Illumina, Inc., Invivoscribe, Inc., Janssen Diagnostics LLC, Luminex Corporation, Myriad Genetics, Inc., Natera, Inc., QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Minimal Residual Disease Testing Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Minimal Residual Disease Testing Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Minimal Residual Disease Testing Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Growing prevalence of cancer worldwide, leading to increased demand for accurate and reliable diagnostic tests
      • 3.2.1.2. Increasing adoption of precision medicine approaches
      • 3.2.1.3. Growing trend towards early cancer diagnosis and detection
    • 3.2.2. Restraints
      • 3.2.2.1. Limited availability of skilled healthcare professionals to perform and interpret MRD tests
      • 3.2.2.2. Concerns over the accuracy and reliability of MRD tests
    • 3.2.3. Opportunities
      • 3.2.3.1. Increasing adoption of advanced technologies, such as next-generation sequencing
      • 3.2.3.2. Growing trend towards personalized cancer care, which requires accurate and reliable measurement
    • 3.2.4. Challenges
      • 3.2.4.1. Need for continuous investment in research and development to stay competitive
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Minimal Residual Disease Testing Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Test Type
      • 4.2.1.1. DNA-Based Test
      • 4.2.1.2. RNA-Based Test
      • 4.2.1.3. Immunological Test
      • 4.2.1.4. Others
    • 4.2.2. By Technology
      • 4.2.2.1. NGS, PCR
      • 4.2.2.2. Flow Cytometry
      • 4.2.2.3. Fluorescence In-Situ Hybridization
      • 4.2.2.4. Others
    • 4.2.3. By Application
      • 4.2.3.1. Hematological Malignancies
      • 4.2.3.2. Solid Tumors
      • 4.2.3.3. Others
    • 4.2.4. By End Use
      • 4.2.4.1. Hospitals
      • 4.2.4.2. Specialty Clinics
      • 4.2.4.3. Diagnostic Laboratories
      • 4.2.4.4. Research and Academic Institutes
      • 4.2.4.5. Others
    • 4.2.5. By Region
      • 4.2.5.1. North America
      • 4.2.5.2. Europe
      • 4.2.5.3. Asia Pacific (APAC)
      • 4.2.5.4. Latin America (LATAM)
      • 4.2.5.5. Middle East and Africa (MEA)

5. North America Minimal Residual Disease Testing Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type
    • 5.2.2. By Technology
    • 5.2.3. By Application
    • 5.2.4. By End Use
    • 5.2.5. By Country
      • 5.2.5.1. United States
      • 5.2.5.1.1. By Test Type
      • 5.2.5.1.2. By Technology
      • 5.2.5.1.3. By Application
      • 5.2.5.1.4. By End Use
      • 5.2.5.2. Canada
      • 5.2.5.2.1. By Test Type
      • 5.2.5.2.2. By Technology
      • 5.2.5.2.3. By Application
      • 5.2.5.2.4. By End Use

6. Europe Minimal Residual Disease Testing Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End Use
    • 6.2.5. By Country
      • 6.2.5.1. Germany
      • 6.2.5.1.1. By Test Type
      • 6.2.5.1.2. By Technology
      • 6.2.5.1.3. By Application
      • 6.2.5.1.4. By End Use
      • 6.2.5.2. United Kingdom
      • 6.2.5.2.1. By Test Type
      • 6.2.5.2.2. By Technology
      • 6.2.5.2.3. By Application
      • 6.2.5.2.4. By End Use
      • 6.2.5.3. Italy
      • 6.2.5.3.1. By Test Type
      • 6.2.5.3.2. By Technology
      • 6.2.5.3.3. By Application
      • 6.2.5.3.4. By End Use
      • 6.2.5.4. France
      • 6.2.5.4.1. By Test Type
      • 6.2.5.4.2. By Technology
      • 6.2.5.4.3. By Application
      • 6.2.5.4.4. By End Use
      • 6.2.5.5. Spain
      • 6.2.5.5.1. By Test Type
      • 6.2.5.5.2. By Technology
      • 6.2.5.5.3. By Application
      • 6.2.5.5.4. By End Use
      • 6.2.5.6. Belgium
      • 6.2.5.6.1. By Test Type
      • 6.2.5.6.2. By Technology
      • 6.2.5.6.3. By Application
      • 6.2.5.6.4. By End Use
      • 6.2.5.7. Russia
      • 6.2.5.7.1. By Test Type
      • 6.2.5.7.2. By Technology
      • 6.2.5.7.3. By Application
      • 6.2.5.7.4. By End Use
      • 6.2.5.8. The Netherlands
      • 6.2.5.8.1. By Test Type
      • 6.2.5.8.2. By Technology
      • 6.2.5.8.3. By Application
      • 6.2.5.8.4. By End Use
      • 6.2.5.9. Rest of Europe
      • 6.2.5.9.1. By Test Type
      • 6.2.5.9.2. By Technology
      • 6.2.5.9.3. By Application
      • 6.2.5.9.4. By End Use

7. Asia-Pacific Minimal Residual Disease Testing Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End Use
    • 7.2.5. By Country
      • 7.2.5.1. China
      • 7.2.5.1.1. By Test Type
      • 7.2.5.1.2. By Technology
      • 7.2.5.1.3. By Application
      • 7.2.5.1.4. By End Use
      • 7.2.5.2. India
      • 7.2.5.2.1. By Test Type
      • 7.2.5.2.2. By Technology
      • 7.2.5.2.3. By Application
      • 7.2.5.2.4. By End Use
      • 7.2.5.3. Japan
      • 7.2.5.3.1. By Test Type
      • 7.2.5.3.2. By Technology
      • 7.2.5.3.3. By Application
      • 7.2.5.3.4. By End Use
      • 7.2.5.4. South Korea
      • 7.2.5.4.1. By Test Type
      • 7.2.5.4.2. By Technology
      • 7.2.5.4.3. By Application
      • 7.2.5.4.4. By End Use
      • 7.2.5.5. Australia & New Zealand
      • 7.2.5.5.1. By Test Type
      • 7.2.5.5.2. By Technology
      • 7.2.5.5.3. By Application
      • 7.2.5.5.4. By End Use
      • 7.2.5.6. Indonesia
      • 7.2.5.6.1. By Test Type
      • 7.2.5.6.2. By Technology
      • 7.2.5.6.3. By Application
      • 7.2.5.6.4. By End Use
      • 7.2.5.7. Malaysia
      • 7.2.5.7.1. By Test Type
      • 7.2.5.7.2. By Technology
      • 7.2.5.7.3. By Application
      • 7.2.5.7.4. By End Use
      • 7.2.5.8. Singapore
      • 7.2.5.8.1. By Test Type
      • 7.2.5.8.2. By Technology
      • 7.2.5.8.3. By Application
      • 7.2.5.8.4. By End Use
      • 7.2.5.9. Vietnam
      • 7.2.5.9.1. By Test Type
      • 7.2.5.9.2. By Technology
      • 7.2.5.9.3. By Application
      • 7.2.5.9.4. By End Use
      • 7.2.5.10. Rest of APAC
      • 7.2.5.10.1. By Test Type
      • 7.2.5.10.2. By Technology
      • 7.2.5.10.3. By Application
      • 7.2.5.10.4. By End Use

8. Latin America Minimal Residual Disease Testing Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End Use
    • 8.2.5. By Country
      • 8.2.5.1. Brazil
      • 8.2.5.1.1. By Test Type
      • 8.2.5.1.2. By Technology
      • 8.2.5.1.3. By Application
      • 8.2.5.1.4. By End Use
      • 8.2.5.2. Mexico
      • 8.2.5.2.1. By Test Type
      • 8.2.5.2.2. By Technology
      • 8.2.5.2.3. By Application
      • 8.2.5.2.4. By End Use
      • 8.2.5.3. Argentina
      • 8.2.5.3.1. By Test Type
      • 8.2.5.3.2. By Technology
      • 8.2.5.3.3. By Application
      • 8.2.5.3.4. By End Use
      • 8.2.5.4. Peru
      • 8.2.5.4.1. By Test Type
      • 8.2.5.4.2. By Technology
      • 8.2.5.4.3. By Application
      • 8.2.5.4.4. By End Use
      • 8.2.5.5. Rest of LATAM
      • 8.2.5.5.1. By Test Type
      • 8.2.5.5.2. By Technology
      • 8.2.5.5.3. By Application
      • 8.2.5.5.4. By End Use

9. Middle East & Africa Minimal Residual Disease Testing Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End Use
    • 9.2.5. By Country
      • 9.2.5.1. Saudi Arabia
      • 9.2.5.1.1. By Test Type
      • 9.2.5.1.2. By Technology
      • 9.2.5.1.3. By Application
      • 9.2.5.1.4. By End Use
      • 9.2.5.2. UAE
      • 9.2.5.2.1. By Test Type
      • 9.2.5.2.2. By Technology
      • 9.2.5.2.3. By Application
      • 9.2.5.2.4. By End Use
      • 9.2.5.3. Qatar
      • 9.2.5.3.1. By Test Type
      • 9.2.5.3.2. By Technology
      • 9.2.5.3.3. By Application
      • 9.2.5.3.4. By End Use
      • 9.2.5.4. Kuwait
      • 9.2.5.4.1. By Test Type
      • 9.2.5.4.2. By Technology
      • 9.2.5.4.3. By Application
      • 9.2.5.4.4. By End Use
      • 9.2.5.5. South Africa
      • 9.2.5.5.1. By Test Type
      • 9.2.5.5.2. By Technology
      • 9.2.5.5.3. By Application
      • 9.2.5.5.4. By End Use
      • 9.2.5.6. Nigeria
      • 9.2.5.6.1. By Test Type
      • 9.2.5.6.2. By Technology
      • 9.2.5.6.3. By Application
      • 9.2.5.6.4. By End Use
      • 9.2.5.7. Algeria
      • 9.2.5.7.1. By Test Type
      • 9.2.5.7.2. By Technology
      • 9.2.5.7.3. By Application
      • 9.2.5.7.4. By End Use
      • 9.2.5.8. Rest of MEA
      • 9.2.5.8.1. By Test Type
      • 9.2.5.8.2. By Technology
      • 9.2.5.8.3. By Application
      • 9.2.5.8.4. By End Use

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Minimal Residual Disease Testing Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Minimal Residual Disease Testing Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Abbott Laboratories
  • 12.2. Adaptive Biotechnologies
  • 12.3. Agilent Technologies
  • 12.4. ARUP Laboratories
  • 12.5. Bio-Rad Laboratories
  • 12.6. F. Hoffmann-La Roche AG
  • 12.7. Illumina, Inc.
  • 12.8. Invivoscribe, Inc.
  • 12.9. Janssen Diagnostics LLC
  • 12.10. Luminex Corporation
  • 12.11. Myriad Genetics, Inc.
  • 12.12. Natera, Inc.
  • 12.13. QIAGEN N.V.
  • 12.14. Sysmex Corporation
  • 12.15. Thermo Fisher Scientific, Inc.
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제